Skip to main content
BMC Cancer logoLink to BMC Cancer
. 2016 Feb 17;16:117. doi: 10.1186/s12885-016-2163-y

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Anastasia S Proskurina 1,#, Tatiana S Gvozdeva 2,#, Ekaterina A Alyamkina 1, Evgenia V Dolgova 1, Konstantin E Orishchenko 1, Valeriy P Nikolin 1, Nelly A Popova 1,3, Sergey V Sidorov 3,4, Elena R Chernykh 5, Alexandr A Ostanin 5, Olga Y Leplina 5, Victoria V Dvornichenko 6,7, Dmitriy M Ponomarenko 6,7, Galina S Soldatova 3,8, Nikolay A Varaksin 9, Tatiana G Ryabicheva 9, Peter N Uchakin 10, Stanislav N Zagrebelniy 3, Vladimir A Rogachev 1, Sergey S Bogachev 1,, Mikhail A Shurdov 11
PMCID: PMC4757989  PMID: 26887451

Erratum

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In this erratum we rectify these mistakes. The full list of authors and the updated Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused.

Corrected Authors’ List:

Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Alyamkina, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin, Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S. Bogachev, and Mikhail A. Shurdov.

Footnotes

The online version of the original article can be found under doi:10.1186/s12885-015-1142-z.

Authors’ contributions

ASP performed the analysis, interpreted the data, and drafted the manuscript. TSG carried out clinical work with patients and drafted the manuscript. EAA carried out the molecular studies. EVD carried out the molecular studies. KEO performed the design of the study and provide the technical conditions for perform works. VPN performed the analysis and interpreted the data. NAP participated in the design of the study. SVS carried out clinical work with patients and participated in study design. ERC participated in the design of the study. AAO performed the analysis and interpreted the data. OYL carried out experiments to estimate the adaptive immunity induction. VVD helped in the data interpretation. DMP carried out clinical work with patients. GSS helped in the data interpretation. NAV, TGR and PNU carried out cytokine analysis. SNZ participated in the design of the study. VAR carried out production of DNA preparation. SSB conceived the study, participated in its design, and coordinated and drafted the manuscript. MAS participated in the study design and coordination. All authors read and approved the final manuscript.

Contributor Information

Anastasia S. Proskurina, Email: asproskurina@gmail.com

Tatiana S. Gvozdeva, Email: ne@spd.name

Ekaterina A. Alyamkina, Email: alamkina@gmail.com

Evgenia V. Dolgova, Email: zhenk123@mail.ru

Konstantin E. Orishchenko, Email: keor@ngs.ru

Valeriy P. Nikolin, Email: nikolin@gorodok.net

Nelly A. Popova, Email: nelly@bionet.nsc.ru

Sergey V. Sidorov, Email: svsidorov@yandex.ru

Elena R. Chernykh, Email: ct_lab@mail.ru

Alexandr A. Ostanin, Email: ostanin62@mail.ru

Olga Y. Leplina, Email: oleplina@mail.ru

Victoria V. Dvornichenko, Email: vv.dvornichenko@gmail.com

Dmitriy M. Ponomarenko, Email: ponomarenkodm@gmail.com

Galina S. Soldatova, Email: sgs@newmail.ru

Nikolay A. Varaksin, Email: varaksin@vector-best.ru

Tatiana G. Ryabicheva, Email: tatria@mail.ru

Stanislav N. Zagrebelniy, Email: snz@post.nsu.ru

Vladimir A. Rogachev, Email: rogachev@bionet.nsc.ru

Sergey S. Bogachev, Phone: +7-383-363-4918, Email: labmolbiol@mail.ru

Mikhail A. Shurdov, Email: shurdov@gmail.com

References

  • 1.Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer. BMC Cancer. 2015;15:122. doi: 10.1186/s12885-015-1142-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES